Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Investment Firm Representing High Net Worth Family Office Invests Broadly Across Therapeutics, Devices, and Diagnostics in USA and Europe

2 Jan

An investment firm that represents a high net worth family office has offices in Western Europe. The firm makes equity investments in life science companies, typically at the Series B stage or later; the firm allocates a total of EUR 3-10 million over the life of an investment. The firm invests in Europe and the US.

In the life science sector, the firm invests in medical applications (therapeutics, diagnostics, and medical devices), life science services and tools, and agtech / food tech. For therapeutics companies, the firm only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and the microbiome.

The firm is a hands-on investor that prefers to take a board seat and work closely with management, and therefore prefers to invest in companies located close to their offices. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Corporate Venture Firm Invests in Early-Stage Life Science Technologies with China Angle and Strong Market Potential

2 Jan

A firm with offices in China is managing two funds in RMB with a total of over 300M RMB, and is planning to raise a USD fund in the near future.

The firm is currently focusing on early-stage (from angel to series A) investments, each investment ranging from 5MM RMB (~0.7MM) to 20MM RMB (~3MM).

With the support of a synergistic incubator business and its accelerating program, as well as a dynamic innovation ecosystem built upon these business arms, the firm has a broad reach of disruptive technologies and is progressively investing in the field of life science to support the business strategy and organic growth of their parent company.

The firm is mainly looking at fields of next generation of molecule diagnostics, microfluidics, synthetic biology, omics technology, bioinformatics, genetic testing, gene therapy and immunotherapy, microbiome, etc. The firm is open to investing in the field of life science and precision medicine, focusing on the frontier research and technologies in DNA, RNA, protein, cell, tissue and other integrative omics. Therapeutics, especially gene therapy, oncology therapy, and eye disease therapy; diagnostics sector, especially in gene detection, molecular diagnostics, CNS and IVD; also some medical devices. However, the firm has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm prefers companies with a China angle, especially companies who are willing to register an entity in China. They mostly are interested in companies with novel and original technologies and a clear direction of clinical applications.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: CVC Arm of Pharmaceutical Company Seeks Digital Health Technologies and Platforms Addressing Chronic Diseases and Other High Unmet Medical Need

2 Jan

A  corporate venture capital arm of a global pharmaceutical with headquarters in Western Europe can invest up to $5m to a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Family Office Associated Investment Firm Seeks Early-Stage Medical Device and Diagnostic Technologies, as well as Therapeutics

2 Jan

An investment firm located in the USA and associate with a family office registered in the Cayman Islands is managing a $100MM fund, the firm invests in angel and seed stage, and its typical allocation size is between $200,000 to $750,000. The firm invests in companies based in the United States, especially in the Silicon Valley area, and normally invests four to five companies every year.

The firm is interested in diagnostics and medical devices in general, especially cancer diagnostics. Regarding therapeutics, it is open to the data platforms for therapeutics and orphan diseases.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Fund Invests US-Wide in 510k Devices

19 Dec

A venture firm based in California makes early stage investments ranging from $100k – $3M, occasionally making larger investments outside of this range.  The firm is flexible in terms of structure with both equity and convertible notes being used. The group will fund, incubate and help develop new technologies at the earliest stages (ideas with no IP) as well as invest in established venture stage companies. The firm will both lead rounds as well as invest with a syndicate. The firm is focused on companies and technologies based in the USA or having their primary business in the USA.

The firm is primarily focused on the medtech and device space, and will evaluate diagnostic technologies that have a device component (tests/IVDS, etc. are not considered). The group is fairly opportunistic, however has specific interests in orthopedics, dermatology, neurovascular, endovascular, women’s health, ophthalmology and general surgical devices and products. The firm is only interested in technologies with a 510(k) regulatory pathway. The group will invest in devices/products in development or at the clinical stage.

The firm has no stricture company or management requirements and is open to working with all entrepreneurs. The company may seek a board seat long with investment, but it is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Worldwide Asset Management Firm Invests in Life Sciences With a China Angle

19 Dec

The proprietary venture capital and private equity arm of a worldwide asset management organization has a fund focused on venture investments related to Greater China.  With an evergreen fund structure, the firm can be flexible in terms of investment sizes (up to $250 million per deal) and horizon. The firm typically makes equity investments. The fund invests in businesses based in China or with a China angle. The firm’s management team also collaborates closely with its parent company’s other funds on international deals.

Within life sciences, the fund works on a wide range of technology sectors including therapeutics, medical devices, diagnostics, biotech R&D services, healthcare IT, and healthcare services. The firm is very opportunistic in terms of subsectors and indications but historically has been active in biosimilars and biotech R&D. The firm evaluates technologies based on two main criteria: meaningful impact on human health; bold and innovative ideas. The firm has no specific preference in the investment stage. However, the firm generally invests in earlier stage for therapeutics and R&D and later stage for medical devices, but seeds have been done with exceptional founding teams.

The fund is seeking companies with a strong and experienced management team. The firm is flexible when it comes to post-investment board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: European VC Invests in Medtech, Diagnostics and Digital Health

19 Dec

A European focused venture capital firm founded in 2015 with partners based in Europe and US is currently actively investing in Spain, Portugal, the UK, and Ireland. The firm is expanding into the Baltics and raising a new €100 million fund. The firm looks for companies mainly in Europe and works closely with the team to expand the business into new markets. The firm invests in series A & series B financings as a Lead or co-Lead with investments ranging from €3 million to €8 million over the life of the company. The firm is actively looking for investment opportunities and plans to make around 12 investments with the new fund over next 4 years. The firm will only invest in private companies.

The firm is an opportunistic investor and will consider medical devices, diagnostics, and healthcare IT companies. The firm is strongly interested in diagnostics and healthcare IT companies as well as data- analytics and IoT companies. Previous investments include a pharmacogenetic test company and a drug delivery technology platform, clinical trial analytics and others. The firm is very opportunistic in terms of subsectors and indications. For therapeutics, the firm will only consider products that are in phase 2 stage or later. In terms of digital health, the firm has interests in consumer-facing platform and analytics areas, such as big data-driven technologies on complex medical research.

The firm looks for management teams with highly relevant experience and strong industry knowledge is a must. The firm looks for management teams that are willing to work alongside a hands-on investor, and the firm always looks to take a board seat. The firm prefers companies to be backed by strong IP protection and must have already raised seed capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: